REQUEST A DEMO
Total
USD $0.00
Search more companies

Zorka Pharma-Hemija D.O.O. Sabac (Serbia)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Zorka Pharma-Hemija D.O.O. Sabac Profile Updated: September 30, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Zorka Pharma-Hemija D.O.O. Sabac is an enterprise located in Serbia, with the main office in Sabac. The enterprise currently operates in the Pharmaceutical and Medicine Manufacturing sector. The company was established on September 12, 2006. 36 (2024) employees currently work for Zorka Pharma-Hemija D.O.O. Sabac. In 2024, the company reported a net sales revenue increase of 40.35%. Its’ total assets recorded a growth of 21.25%. In 2024, Zorka Pharma-Hemija D.O.O. Sabac’s net profit margin increased by 3.27%.

Headquarters
Hajduk Veljkova bb
Sabac; Macva;

Contact Details: Purchase the Zorka Pharma-Hemija D.O.O. Sabac report to view the information.

Website: http://www.zorkahemija.com

Basic Information
Total Employees:
Purchase the Zorka Pharma-Hemija D.O.O. Sabac report to view the information.
Registered Capital:
Purchase the Zorka Pharma-Hemija D.O.O. Sabac report to view the information.
Financial Auditors:
Purchase the Zorka Pharma-Hemija D.O.O. Sabac report to view the information.
Incorporation Date:
September 12, 2006
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Procurator
Purchase this report to view the information.
Representative
Ownership Details
Purchase this report to view the information.
53.25%
Purchase this report to view the information.
46.75%
Subsidiaries
Zorka Bpd D.O.O. Sabac
18%
Pan-Alko Promet Proizvodno Trgovinsko Preduzece D.O.O. Kula
0.01%
Company Performance
Financial values in the chart are available after Zorka Pharma-Hemija D.O.O. Sabac report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
40.35%
Total operating revenue
41.29%
Operating profit (EBIT)
122.16%
EBITDA
101.57%
Net Profit (Loss) for the Period
97.12%
Total Assets
21.25%
Total Equity
23.85%
Operating Profit Margin (ROS)
4.95%
Net Profit Margin
3.27%
Return on Equity (ROE)
7.16%
Debt/Equity
-0.16%
Quick Ratio
0.38%
Cash Ratio
0.35%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?